| Officer | Age | In this role | 2025 pay | Source |
|---|---|---|---|---|
|
Ryan Cohlhepp
Also a director
President, COO & Interim CEO
Title from the Form 4 dated Sep 8, 2026
|
49 | Not stated | $858,400 | |
|
Claire Mazumdar
Also a director
Chief Executive Officer
Title from the Form 4 dated Aug 10, 2026
|
36 | Not stated | $927,688 | |
|
Ivan Hyep
Chief Financial Officer and Treasurer
|
41 | Not stated | Not reported | |
|
Jennifer Larson
Chief Financial Officer
Title from the Form 4 dated Aug 12, 2026
|
Not stated | Not stated | Not reported | |
|
Lara Meisner
Chief Legal Officer, Compliance Officer and Corporate Secretary
|
54 | Not stated | Not reported | |
|
David Raben
Chief Medical Officer
|
62 |
Since 2023
3 years
|
$709,164 | |
|
William Schelman
Chief Medical Officer
Title from the Form 4 dated May 8, 2026
|
Not stated | Not stated | Not reported |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
From the proxy statement filed Apr 27, 2026 · updated by the 8-K of Jul 28, 2026
| Director | Age | On board | Independent | Committees | Other public boards | 2025 pay | Source |
|---|---|---|---|---|---|---|---|
|
Michael Powell
Board chair
|
71 |
2024
2 years
|
Independent |
Audit Committee
|
None stated | Not stated | |
|
Claire Mazumdar
CEO
|
36 |
2020
6 years
|
Not independent | None stated | Relay Therapeutics, Inc. | Paid as CEO | |
|
Ryan Cohlhepp
Executive officer
|
49 |
2024
2 years
|
Not independent | None stated | None stated | Not stated | |
|
Christopher Bowden
|
65 |
2024
2 years
|
Independent |
Compensation Committee
|
None stated | $253,634 | |
|
Carolyn Ng
|
42 |
2023
3 years
|
Independent |
Audit Committee
Nominating and Corporate Governance Committee
|
None stated | Not stated | |
|
Jake Simson
|
40 |
2023
3 years
|
Independent |
Nominating and Corporate Governance Committee
|
Tyra Biosciences, Inc., Septerna, Inc., Janux Therapeutics, Inc. | Not stated | |
|
Kate Haviland
|
50 |
2023
3 years
|
Independent |
Compensation Committee
Launch Readiness Committee · Chair
|
Fulcrum Therapeutics, Inc. | $253,634 | |
|
Scott Robertson
|
46 |
2023
3 years
|
Independent |
Audit Committee · Chair
|
None stated | $263,634 | |
|
Jeremy Bender
Joined Jul 28, 2026
|
- | - | Independent |
Audit Committee
Launch Readiness Committee
|
- | - | |
|
Christy Oliger
Joined Jul 28, 2026
|
- | - | Independent |
Nominating and Corporate Governance Committee
Launch Readiness Committee
|
- | - | |
|
Nils Lonberg
Leaving at the meeting
|
70 |
2019
7 years
|
Independent | None stated | None stated | Not stated |
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive. A director marked Joined was added by an 8-K; their row opens that 8-K, and a dash is a value it does not give.
The proxy filed Apr 27, 2026 describes a review policy but reports no transactions.
Read the policy in the proxyLoading...